Treating Rosacea

U.S. Pharmacist

Volumn 32, Issue 9, 2007, Pages 45-53

  Norwood, Rhonda ^a   Norwood, Daryl ^b  

^a PALM BEACH ATLANTIC UNIVERSITY   (United States)

^b FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZELAIC ACID; AZITHROMYCIN; BENZOYL PEROXIDE; CLARITHROMYCIN; CLINDAMYCIN; COSMETIC; DOXYCYCLINE; ERYTHROMYCIN; ISOTRETINOIN; MACROLIDE; METRONIDAZOLE; MINOCYCLINE; OXYTETRACYCLINE; PLACEBO; SULFACETAMIDE; SULFONAMIDE; SULFUR; SUNSCREEN; TETRACYCLINE;

ACNE; ANEMIA; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; ARTICLE; BONE PAIN; BURNING SENSATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTACT DERMATITIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EPISTAXIS; ERYTHEMA; EYE DISEASE; EYE INFLAMMATION; GASTROINTESTINAL IRRITATION; HELICOBACTER PYLORI; HUMAN; INTRAHEPATIC CHOLESTASIS; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; MONOTHERAPY; NEPHROTOXICITY; PAPULE; PATHOGENESIS; PHOTOTHERAPY; PREGNANT WOMAN; PROTECTIVE CLOTHING; PRURITUS; PUSTULE; RISK FACTOR; ROSACEA; SKIN BURNING SENSATION; SKIN EDEMA; SKIN INFECTION; SKIN IRRITATION; SKIN MANIFESTATION; SKIN REDNESS; TELANGIECTASIA; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; XEROSIS;

EID: 47749120286     PISSN: 01484818     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (36)

1. Crawford G, Pelle M, James W. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341.
2. Fernandez A. Oral use of azithromycin for the treatment of rosacea. Arch Dermatol. 2004;140:489-490.
3. Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: Report of the national rosacea society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50:907-912.
4. Cohen A, Tiemstra J. Diagnosis and treatment of rosacea. J Am Board Fam Pract. 2002;15:214-217.
5. Pelle M, Crawford G, James W. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51:499-512.
6. Nally J, Berson D. Topical therapies for rosacea. J Drugs Dermatol. 2006;5:23-27.
7. Nielsen PG. A double blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol. 1983;109:63-65.
8. Nielsen PG. Treatment of rosacea with 1% metronidazole cream. A double blind study. Br J Dermatol. 1983;108:327-332.
9. Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Arch Dermatol. 1987;123:609-614.
10. Breneman D, Stewart D, Hevia O, et al. A double-blind, multicenter clinical trial comparing efficacy of once daily metronidazole 1% to vehicle in patients with rosacea. Cutis. 1998;61:44-47.
11. Jorizzo J, Lebwohl M, Tobey R. The efficacy of metranidazole 1% cream once daily compared with metronidazole 1% twice daily and their vehicles in rosacea: a double blind clinical trial. J Am Acad Dermatol. 1998;39:502-504.
12. Dahl M, Jarratt M, Kaplan D, et al. Once daily topical metronidazole cream formulations in the treatment of papules and pustules of rosacea. J Am Acad Dermatol. 2001;45:723-730.
13. Zip C. An update on the role of topical metronidazole in rosacea. Skin Therapy Lett. 2006;11:1-4.
14. Del Rosso J. Topical therapy for rosacea: a status report. Practical Dermatology. 2004:43-46.
15. Dahl MV, Katz HL, Krueger GG, et al. Topical metronidazole maintains remission of rosacea. Arch Dermatol. 1998;134:679-683.
16. Wilkin J. Use of topical products for maintaining remission in rosacea. Arch Dermatol. 1999;135:79-80.
17. Mackley CL, Thiboutot DM. Diagnosing and managing the patient with rosacea. Cutis. 2005;75:25-29.
18. Saunder D, Miller R, Gratton D, et al. The treatment of rosacea: safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion is demonstrated in a double blind study. J Dermatol Treat. 1997;8:79-85.
19. Del Rosso J. A status report on the medical management of rosacea: focus on topical therapies. Cutis. 2002;70:271-275.
20. Lacy C, Armstrong L, Goldman M, et al. Drug Information Handbook. 10th ed. Hudson, OH: Lexi-Comp; 2002-2003:1268-1269.
21. Thiboutot D, Theiroff R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as new treatment for papulopustular rosacea: results from two randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845.
22. Elewski B, Fleischer A, Pariser D. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea. Arch Dermatol. 2003;139:1444-1450.
23. Mills H, Kligman M. Topically applied erythromycin in rosacea. Arch Dermatol. 1976; 112:553-554.
24. Blount W, Pelletier A. Rosacea: a common, yet commonly overlooked, condition. Am Family Physician. 2002;66:435-442.
25. Wilkin J, Dewitt S. Treatment of rosacea: topical clindamycin versus oral tetracycline. Int J Dermatol. 1993;32:65-67.
26. Bladwin H. Oral therapy for rosacea. J Drugs Dermatol. 2006;5:16-21.
27. Bikowski J. Subantimicrobial dose doxycycline for acne and rosacea. SKINmed. 2003;2:234-245.
28. Oracea [package insert]. Newton, PA: CollaGenex Pharmaceuticals Inc.; May 2006.
29. Rosso D. Results of phase 3 clinical trials of Oracea. Dermatology Times. 2005;26(9):34. Abstract.
30. Lacy C, Armstrong L, Goldman M, et al. Drug Information Handbook. 10th ed. Hudson, OH: Lexi-Comp; 2002-2003:1306-1308.
31. Torresani C, Pavesi A, Manara G. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol. 1997;36:942-946.
32. Bakar O, Demircay Z, Gurbuz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol. 2004;43:151.
33. Erdogan F, Yurtsever P, Aksoy D, et al. Efficacy of low dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1998; 134:884-885.
34. Accutane [package insert]. Nutley, NJ: Roche Inc.; August 2005.
35. Lonne-Rahm S, Nordlind K, Wiegleb D, et al. Laser Treatment of Rosacea. Arch Dermatol. 2004;140:1345-1349.
36. Sadick N. A structural approach to nonablative rejuvenation. Cosmetic Dermatol. 2002; 15:39-43.